- A Case of Paronychia Occurring after Injection with Cetuximab (Erbitux(R), IMC-C225)
-
Shin MK, Kang IJ, Kim SY, Lee MH
- KMID: 2248937
- Korean J Dermatol.
- 2006 Aug;44(8):1007-1009.
We report a case of paronychia induced by cetuximab in a 43-year-old woman. Cetuximab is an antibody to the epidermal growth factor receptor, and has previously been shown to block... -
- CITED
-
- Close
- SHARE
-
- Close
- Targeted Molecular Therapy in a Murine Model of Oral Squamous Cell Carcinoma with an Epidermal Growth Factor Receptor Inhibitor
-
Park YW
- KMID: 2186647
- J Korean Assoc Maxillofac Plast Reconstr Surg.
- 2009 Jan;31(1):8-17.
PURPOSE: We determined the therapeutic effect of an epidermal growth factor receptor (EGFR)-specific monoclonal antibody (mAb), cetuximab (Erbitux) on the growth of oral squamous cell carcinoma (OSCC) xenografted in athymic... -
- CITED
-
- Close
- SHARE
-
- Close
- A Case of Acneiform Eruption Occurring after Injection of Cetuximab (Erbitux(R), IMC-C225)
-
Choi YL, Lee KJ, Park HS, Kim WS, Lee JH, Yang JM, Lee ES, Lee DY
- KMID: 2249389
- Korean J Dermatol.
- 2005 Oct;43(10):1423-1425.
We report a case of acneiform skin eruption induced by cetuximab in a 58-year-old man. Cetuximab is a new anticancer agent, which acts as a selective epidermal growth factor receptor... -
- CITED
-
- Close
- SHARE
-
- Close
- Cetuximab Related Eyelash Elongations for Patients with Metastatic Rectum Carcinoma: Metabolic Complete Response
-
Urun Y, Utkan G
- KMID: 2265075
- Ann Dermatol.
- 2013 Nov;25(4):504-505.
- doi: 10.5021/ad.2013.25.4.504
No abstract available. -
- CITED
-
- Close
- SHARE
-
- Close
- Successful rapid desensitization for cetuximab-induced anaphylaxis
-
Won HK, Moon SD, Shim JS, Chung SJ, Kim GW, Kim SJ, Park HK, Kang HR
- KMID: 2218660
- Allergy Asthma Respir Dis.
- 2015 Jul;3(4):294-296.
- doi: 10.4168/aard.2015.3.4.294
Cetuximab, a chimeric mouse-human immunoglobulin, is an antiepidermal growth factor receptor monoclonal antibody. It has been approved by the U.S. Food and Drug Administration for the treatment of metastatic colorectal... -
- CITED
-
- Close
- SHARE
-
- Close
- Retrospective Analysis of Patients Treated with Cetuximab plus FOLFIRI for Previous Irinotecan-combined Chemotherapy in Metastatic Colorectal Cancer
-
Park JW, Moon SM, Hwang DY
- KMID: 2198873
- J Korean Soc Coloproctol.
- 2008 Oct;24(5):345-350.
- doi: 10.3393/jksc.2008.24.5.345
PURPOSE: Many reports about efficacy of cetuximab in the prolongation of survival have been published. Especially, the combination of cetuximab and FOLFIRI has a high activity even in prior irinotecan... -
- CITED
-
- Close
- SHARE
-
- Close
- The effect of near-infrared fluorescence conjugation on the anti-cancer potential of cetuximab
-
Yun JY, Hyun BH, Nam SY, Yun YW, Lee HJ, Lee BJ
- KMID: 2430883
- Lab Anim Res.
- 2018 Mar;34(1):30-36.
- doi: 10.5625/lar.2018.34.1.30
This study investigated the anti-cancer potential of a near-infrared fluorescence (NIRF) molecule conjugated with Cetuximab (Cetuximab-NIRF) in six-week-old female BALB/c athymic (nu+/nu+) nude mice. A431 cells were cultured and injected... -
- CITED
-
- Close
- SHARE
-
- Close
- Use of a High-Throughput Genotyping Platform (OncoMap) for RAS Mutational Analysis to Predict Cetuximab Efficacy in Patients with Metastatic Colorectal Cancer
-
Kim D, Hong YS, Kim JE, Kim KP, Lee JL, Chun SM, Kim J, Jang SJ, Kim TW
- KMID: 2367501
- Cancer Res Treat.
- 2017 Jan;49(1):37-43.
- doi: 10.4143/crt.2016.069
PURPOSE: Cetuximab demonstrates improved efficacy outcomes in patients with metastatic colorectal cancer (mCRC) harboring wild-type KRAS exon 2. Resistance to cetuximab is mediated by activating less frequent mutations in the... -
- CITED
-
- Close
- SHARE
-
- Close
- Immunotherapy in Head and Neck Squamous Cell Cancer
-
Denaro N, Merlano MC
- KMID: 2439847
- Clin Exp Otorhinolaryngol.
- 2018 Dec;11(4):217-223.
- doi: 10.21053/ceo.2018.00150
Prognosis in relapsed metastatic head and neck squamous cell cancer (RM-HNSCC) is dismal. Platinum based chemotherapy in combination with Cetuximab is used in first-line setting, while no further validated options... -
- CITED
-
- Close
- SHARE
-
- Close
- Chemotherapy of Head and Neck Cancer
-
Yeo CK
- KMID: 2277896
- Korean J Otorhinolaryngol-Head Neck Surg.
- 2014 May;57(5):291-296.
- doi: 10.3342/kjorl-hns.2014.57.5.291
Head and neck cancers comprise a heterogenous group of cancers that require a multidisciplinary approach. Surgery, radiation therapy, chemotherapy and, more recently, target therapy are often employed in various combinations... -
- CITED
-
- Close
- SHARE
-
- Close
- The Role of Targeted Therapy in the Treatment of Metastatic Colorectal Cancer
-
Kim HJ, Oh ST
- KMID: 2199209
- J Korean Soc Coloproctol.
- 2007 Dec;23(6):524-532.
- doi: 10.3393/jksc.2007.23.6.524
Colorectal cancer is the fourth most common malignant disease in Korea. Until recently, fluorouracil was the only effective chemotherapeutic agent for colorectal cancer. But during the past decades, the Food... -
- CITED
-
- Close
- SHARE
-
- Close
- Two Cases of Acneiform Eruption Caused by Epidermal Growth Factor Receptor Inhibitors
-
Choi KW, Lee CY, Lee YK, Kim HS, Kim KH, Kim YH
- KMID: 2248163
- Korean J Dermatol.
- 2008 Jun;46(6):862-865.
Epidermal growth factor receptor (EGFR) inhibitors are associated with unique and dramatical dermatological side effects. The most commonly encountered adverse effect is a mild skin toxicity characterized by a sterile... -
- CITED
-
- Close
- SHARE
-
- Close
- Clinical Features of the Cutaneous Adverse Events Induced by Combination Chemotherapy that Includes Cetuximab (Erbitux(R))
-
Chung WK, Chang SE, Ryu MH, Lee MW, Choi JH, Moon KC, Koh JK
- KMID: 2248022
- Korean J Dermatol.
- 2008 Nov;46(11):1478-1487.
BACKGROUND: Epidermal growth factor receptor (EGFR) inhibitors are associated with cutaneous adverse events, including papulopustular eruption, xerosis, paronychia, hair abnormality and mucositis. In particular, acneiform eruptions might serve as the... -
- CITED
-
- Close
- SHARE
-
- Close
- Tick-induced allergies: mammalian meat allergy, tick anaphylaxis and their significance
-
van Nunen
- KMID: 2397062
- Asia Pac Allergy.
- 2015 Jan;5(1):3-16.
- doi: 10.5415/apallergy.2015.5.1.3
Serious tick-induced allergies comprise mammalian meat allergy following tick bites and tick anaphylaxis. Mammalian meat allergy is an emergent allergy, increasingly prevalent in tick-endemic areas of Australia and the United... -
- CITED
-
- Close
- SHARE
-
- Close
- Chemotherapy for Colorectal Cancer
-
Hong YS, Kim TW
- KMID: 2188334
- J Korean Med Assoc.
- 2010 Jul;53(7):582-591.
- doi: 10.5124/jkma.2010.53.7.582
Survival outcomes have been steadily improving for last 50 years in patients with colorectal cancer. The 5-fluorouracil (5-FU) is still one of the major chemotherapeutic agents. New cytotoxic agents, irinotecan... -
- CITED
-
- Close
- SHARE
-
- Close
- Target Therapy in Unresectable or Metastatic Colorectal Cancer
-
Kim JH, Park SJ
- KMID: 2383460
- Korean J Gastroenterol.
- 2016 Dec;68(6):303-311.
- doi: 10.4166/kjg.2016.68.6.303
Colorectal cancer (CRC) is the third most commonly diagnosed cancer in Korea. Despite recent developments in the treatment of CRC, the median overall survival time in patients with metastatic CRC... -
- CITED
-
- Close
- SHARE
-
- Close
- Carbohydrates as food allergens
-
Soh JY, Huang CH, Lee BW
- KMID: 2397063
- Asia Pac Allergy.
- 2015 Jan;5(1):17-24.
- doi: 10.5415/apallergy.2015.5.1.17
The literature supports the notion that carbohydrate epitopes, on their own, do not contribute significantly to the induction of allergic reactions. They bind weakly to IgE antibodies and have been... -
- CITED
-
- Close
- SHARE
-
- Close
- Cutaneous Adverse Reactions Associated with Epidermal Growth Factor Receptor Inhibitors
-
Lee HJ, Sim HS, Seo JK, Lee D, Sung HS
- KMID: 2303577
- Korean J Dermatol.
- 2011 Feb;49(2):131-140.
BACKGROUND: Cutaneous adverse reactions are often observed during chemotherapy with epidermal growth factor receptor (EGFR) inhibitors including papulopustular eruptions, xerosis and paronychia. OBJECTIVE: To investigate and compare the cutaneous adverse reactions... -
- CITED
-
- Close
- SHARE
-
- Close
- Affinity Maturation of an Epidermal Growth Factor Receptor Targeting Human Monoclonal Antibody ER414 by CDR Mutation
-
Chang KH, Kim MS, Hong GW, Seo MS, Shin YN, Kim SH
- KMID: 2424210
- Immune Netw.
- 2012 Aug;12(4):155-164.
It is well established that blocking the interaction of EGFR with growth factors leads to the arrest of tumor growth, resulting in tumor cell death. ER414 is a human monoclonal... -
- CITED
-
- Close
- SHARE
-
- Close
- Current Development and Research Trend of Chemotherapeutic Agents for Head and Neck Squamous Cell Carcinoma
-
Lee YS
- KMID: 2461000
- Korean J Otorhinolaryngol-Head Neck Surg.
- 2019 Sep;62(9):487-498.
- doi: 10.3342/kjorl-hns.2019.00479
After FDA approval of cetuximab at 2006, receptor tyrosine kinase, including an epidermal growth factor receptor, blocking agents have been evaluated for head and neck squamous cell carcinoma (HNSCC). Agents... -
- CITED
-
- Close
- SHARE
-
- Close
